News & Updates

Mental wellbeing during a pandemic

The recurrent waves of the COVID-19 pandemic are having a significant impact on healthcare workers, and Medical Protection has called for more to be done globally to ensure that medical professionals have quick access to mental wellbeing support.

Product Highlight - Enhertu

Trastuzumab deruxtecan 100 mg powder for concentrate for solution for infusion

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Sacituzumab govitecan confers survival benefit in Asian patients with mBC

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

Experts call for increased oral contraceptive use in China

Experts are calling for more education to increase the use of combination oral contraceptives (COCs) in China as up to 10 million abortions are performed each year for unwanted pregnancies.

Deliberating screening for gynaecological cancer

Screening for cervical cancer remains more critical than that for endometrial and ovarian cancers, says a specialist.

Incident, proliferative benign breast disease tied to greatest breast cancer risk

Women with incident, proliferative benign breast diseases (BBDs) may have an elevated risk of developing breast cancer, according to a retrospective study conducted in Spain.

The Impact of Social Media on Adolescent Mental Health

This topic examines how social media usage affects the mental health of adolescents, focusing on both positive and negative outcomes, including issues like anxiety, depression, body image concerns, and social comparison, as well as potential benefits such as social support and community building.

[JM Test] Superovulation combined with intrauterine insemination yields higher pregnancy rates

Combined administration of superovulation (SO) and intrauterine insemination (IUI) yields higher pregnancy rates (PR) compared to either IUI, timed intercourse (TI), or SO alone, says an expert.

ACOG article 2.3

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.